SMSarah H. Millan

Sarah H. Millan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah H. Millan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Amanda D. Currie

    Department of Neurology, Vanderbilt University Medical Center, 1611 21st Ave S., A-0118 Medical Center North, Nashville, TN 37223-2551, USA

    1 shared publication
  • Ann Hu

    Georgetown University School of Medicine Washington DC USA

    1 shared publication
  • Anna L. Molinari

    Department of Neurology, Vanderbilt University Medical Center, 1611 21st Ave S., A-0118 Medical Center North, Nashville, TN 37223-2551, USA

    1 shared publication
  • Ben W. Gratz

    Georgetown University School of Medicine, Washington, DC, USA

    1 shared publication
  • Claudia Fernandez Perez

    Georgetown University School of Medicine Washington DC USA

    1 shared publication
  • Holly D. Shan

    Georgetown University School of Medicine Washington DC USA

    1 shared publication

Latest Publications

  • Open Access

    Treatment Strategies for Pediatric Trichotillomania: State‐of‐the‐Art Review on Progress and Persistent Challenges

    by Sheila Sharifi, Mariah Estill, Lea Tordjman, Sarah H. Millan, Jessica X. Ouyang

    Trichotillomania (TTM) is a condition characterized by recurrent hair pulling, often resulting in hair loss and functional impairment. The disorder remains underreported in the pediatric population, despite high rates of psychiatric comorbidities. Moreover, diagnosing and treating TTM among children remains challenging due to a lack of standardized guidelines. Hence, this systematic review aims to evaluate the current treatment approaches for pediatric TTM. A comprehensive search was conducted of five databases, using the search concepts of trichotillomania, pediatric populations, and treatments/interventions. Studies were included if they (1) directly addressed the topic, (2) were of an appropriate study type (e.g., clinical trials, case–control studies, cohort studies, cross‐sectional studies, or interview studies), (3) were published within the past 10 years, and (4) appeared in peer‐reviewed journals published in English. Ultimately, 10 studies met our inclusion criteria, from which data were extracted and synthesized following formal quality assessment. Our results indicate that behavioral interventions, particularly habit reversal training, consistently demonstrated the greatest therapeutic benefit. Pharmacological treatments, including selective serotonin reuptake inhibitors, have been explored in various case series. Although some individuals have shown improvement, overall evidence remains insufficient to support pharmacotherapy as first‐line. Alternative therapies, such as N‐acetylcysteine, have also been studied, though findings are variable and require further investigation in pediatric cohorts. Our review underscores the importance of early behavioral intervention and the need for larger, controlled studies to inform standardized treatment protocols. Given the functional and psychosocial burden of TTM in youth, comprehensive management strategies are essential.


  • Chronic Venous Insufficiency Associated With Nonconscious Proprioception Irregularities

    by Umayr R. Shaikh, Wynne Zheng, Ben W. Gratz, Ann Hu, Sarah H. Millan, Holly D. Shan, Lydia Hu, Luke Llaurado, Claudia Fernandez Perez, Jie Jung Shih, et al.

  • Open Access

    Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Is Not Associated with Increased Body Mass Index

    by Sarah H. Millan, Mallory L. Hacker, Maxim Turchan, Anna L. Molinari, Amanda D. Currie, David Charles

    Previous studies suggest that deep brain stimulation of the subthalamic nucleus (STN-DBS) for Parkinson’s disease (PD) leads to weight gain. This study analyzes changes in body mass index (BMI) in 29 subjects from a prospective, single-blind trial of DBS in early stage PD (age 50–75, Hoehn & Yahr stage II off medication, treated with antiparkinsonian medications for ≥6 months but <4 years, and without a history of motor fluctuations, dyskinesias, or dementia). Subjects were randomized to DBS plus optimal drug therapy (DBS+ODT;n=15) or ODT (n=14) and followed for 24 months. Weight and height were recorded at baseline and each follow-up visit and used to calculate BMI. BMIs were compared within and between groups using nonparametrict-tests. Mean BMI at baseline was 29.7 in the ODT group and 32.3 in the DBS+ODT group (p>0.05). BMI change over two years was not different between the groups (p=0.62, ODT = −0.89; DBS+ODT = −0.17). This study suggests that STN-DBS is not associated with weight gain in subjects with early stage PD. This finding will be tested in an upcoming FDA-approved phase III multicenter, randomized, double-blind, placebo-controlled, pivotal clinical trial evaluating DBS in early stage PD (ClinicalTrials.gov identifierNCT00282152).